Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARD | Q03181 | 7/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23244694 | 0.88 | LMNA (0.33) | LMNA | |
| SCHEMBL23236368 | 0.79 | — | — | |
| SCHEMBL23236277 | 0.79 | — | — | |
| SCHEMBL23236217 | 0.79 | — | — | |
| SCHEMBL23236179 | 0.74 | — | — | |
| SCHEMBL23236137 | 0.74 | — | — | |
| SCHEMBL23236362 | 0.74 | — | — | |
| SCHEMBL23236302 | 0.74 | — | — | |
| SCHEMBL23236180 | 0.74 | — | — | |
| SCHEMBL23236135 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530176-B2 | Processes for preparing a 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl carboxylate compound and hydroxymethyl 1,2,2-trimethyl-3-cyclopentenyl ketone, and a halomethyl (1,2,2-trimethyl-3-cyclopentenyl) ketone compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-12-20 | — | — | US | disclosed |
| US-20210114960-A1 | PROCESSES FOR PREPARING A 2-(1,2,2-TRIMETHYL-3-CYCLOPENTENYL)-2-OXOETHYL CARBOXYLATE COMPOUND AND HYDROXYMETHYL 1,2,2-TRIMETHYL-3-CYCLOPENTENYL KETONE, AND A HALOMETHYL (1,2,2-TRIMETHYL-3-CYCLOPENTENYL) KETONE COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| CN-112661636-A | Acyloxy and hydroxyketone compound containing 1,2, 2-trimethyl-3-cyclopentenyl and preparation method thereof | 信越化学工业株式会社 | 2021-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114960-A1 | PROCESSES FOR PREPARING A 2-(1,2,2-TRIMETHYL-3-CYCLOPENTENYL)-2-OXOETHYL CARBOXYLATE COMPOUND AND HYDROXYMETHYL 1,2,2-TRIMETHYL-3-CYCLOPENTENYL KETONE, AND A HALOMETHYL (1,2,2-TRIMETHYL-3-CYCLOPENTENYL) KETONE COMPOUND | TET1, FTO, TET3 | TSHR 1909/4885LMNA 2087/4885NFKB1 3871/4885 |
| US-11530176-B2 | Processes for preparing a 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl carboxylate compound and hydroxymethyl 1,2,2-trimethyl-3-cyclopentenyl ketone, and a halomethyl (1,2,2-trimethyl-3-cyclopentenyl) ketone compound | TET1, FTO, TET3 | TSHR 1909/4885LMNA 2087/4885NFKB1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.